CGTN
19.8.2020 14:12:04 CEST | Business Wire | Press release
Chinese President Xi Jinping arrived in east China's Anhui Province for an inspection tour on Tuesday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200819005372/en/
Xi, also general secretary of the Communist Party of China Central Committee, visited the floodgate of the Wangjiaba Dam on the Huaihe River and other flood-hit areas in Funan County, Fuyang City. He also went to a "zhuangtai," a residential structure built on raised ground at a higher elevation that functions as a haven from river floods.
Since June, Anhui has been ravaged by floods and landslides caused by incessant heavy rains.
The president also met with local officials and residents and learned about flood prevention and disaster relief work and the progress of recovery efforts.
This is President Xi's latest inspection tour this year, following his visits to Yunnan Province , Beijing Municipality , Hubei Province , Zhejiang Province , Shaanxi Province , Shanxi Province , Ningxia Hui Autonomous Region and Jilin Province .
People-centered efforts
"I have always been concerned about the people in flood-stricken areas," Xi said while meeting locals, adding that he felt ease after seeing villagers had a place to live and had restarted production.
Severe rainstorms have hit many regions in China this summer, triggering flooding of rivers. According to the Ministry of Emergency Management (MEM), 54.8 million people in 27 provincial-level regions have been affected.
Chinese leaders have called for unrelenting efforts to ensure the safety of people's lives and property.
During a CPC leadership meeting on July 17, President Xi stressed putting people's lives and property first and taking more forceful measures to do well in flood control and relief work.
China has made all-out efforts in flood control and disaster relief with massive mobilization, evacuations and a top-level emergency response in several hard-hit provinces.
Through the nationwide joint efforts, the MEM said, the number of deaths and missing due to floods fell by 53.9 percent from with the national average of the past five years. The number of evacuated people increased by 36.7 percent, the ministry added.
Enhance capabilities to cope with natural disasters
Noting that China has fought against natural disasters for thousands of years, Xi on Tuesday also urged respect for nature, harmony between humans and nature and efforts to improve capabilities to cope with natural disasters.
"We should modernize our ability to prevent and combat natural disasters in our effort to build a modern socialist country in an all-round way," Xi added.
Hailed as the "most important floodgate on the Huaihe River," the floodgate of the Wangjiaba Dam sets a good example of China's flood preparation.
The floodgate, built in 1953 was opened for the 16th time on July 20 to store water, intercepting 375 million cubic meters of potential floodwater by July 23 when it was closed.
The CPC leadership meeting on July 17 also stressed that China needs to comprehensively enhance its disaster prevention capability and will include capacity building on disaster prevention in its 14th Five-Year Plan covering the period 2021-2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200819005372/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
